Like most websites, we use cookies and other similar technologies for a number of reasons, such as keeping our website reliable and secure, personalizing content, providing social media features and to better understand how our site is used. By using our site, you are agreeing to our use of these tools. Learn More

Your Location is set to:

CAMBRIA-1

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy -- NCT05774951

Objective

This clinical trial aims to improve cancer free-survival in patients with hormone positive early breast cancer with intermediate to high risk for disease recurrence after locoregional and systemic therapy with the next generation oral selective estrogen receptor degrader (SERD), Camizestrant. Objective is to demonstrate superiority of extended therapy with Camizestrant as compared to standard endocrine therapy by assessment of invasive breast cancer-free survival.

Principal Investigator(s)
Edward Wyluda, DO

Clinical Trial Categories

  • Treatment
  • Breast Cancer
Contact
Christine Neely-Jones, RN at 508-862-7298
or cneelyjones@capecodhealth.org
How to Participate

Contact your oncologist, oncology nurse or the Oncology Research Program Manager.